Ionis Pharmaceuticals Holds Annual Stockholders Meeting

An update from Ionis Pharmaceuticals ( (IONS) ) is now available.

Ionis Pharmaceuticals held its virtual Annual Meeting of Stockholders on June 5, 2025, where four proposals were considered. The stockholders elected directors to serve until the 2028 Annual Meeting, approved executive compensation on an advisory basis, authorized an increase in shares under the 2011 Equity Incentive Plan, and ratified the selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year. These approvals reflect continued support for the company’s strategic direction and governance structure.

The most recent analyst rating on (IONS) stock is a Hold with a $55.00 price target. To see the full list of analyst forecasts on Ionis Pharmaceuticals stock, see the IONS Stock Forecast page.

Spark’s Take on IONS Stock

According to Spark, TipRanks’ AI Analyst, IONS is a Neutral.

Ionis Pharmaceuticals’ overall stock score is primarily influenced by significant financial challenges, offset by positive earnings guidance and promising product developments. Financial performance remains a critical concern, but strategic product launches and improved guidance provide a positive outlook, contributing to a moderate overall score.

To see Spark’s full report on IONS stock, click here.

More about Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of RNA-targeted therapeutics. The company is known for its innovative approach to drug discovery and development, primarily targeting genetic disorders and other serious diseases.

Average Trading Volume: 1,647,713

Technical Sentiment Signal: Sell

Current Market Cap: $5.62B

Learn more about IONS stock on TipRanks’ Stock Analysis page.